Vaccine Research & Development
The Sabin Vaccine Institute supports innovative technologies and approaches in vaccine research and development to combat infectious and emerging threats to global health. Sabin’s R&D strategy is to advance the development of vaccine candidates that have demonstrated early scientific value but have little commercial value, targeting diseases that impact the world's most vulnerable populations. Sabin leverages the expertise of partners in the academic, public and private sectors, and promotes open-source research.
Ebola has taken the lives of more than 13,000 people in recent years. To protect communities across the globe from the critical threat posed by Ebola and the closely related, but lesser known, Marburg virus, Sabin is preparing to advance the development of several vaccines by exclusively licensing the technology for three clinical-stage candidate vaccines from GSK. The agreement involves prophylactic candidate vaccines to protect against Ebola Zaire, Ebola Sudan and Marburg virus, all based on GSK’s proprietary ChAd3 platform. In an additional agreement, Sabin is partnering with the Vaccine Research Center at the National Institute of Allergy and Infectious Disease to continue development of these vaccines.
For more than a decade, Sabin conducted research to develop new, low-cost vaccines for diseases impacting the world's most neglected and vulnerable populations, including the first and only vaccine candidate for human hookworm to be assessed in clinical trials, and vaccine candidates for intestinal schistosomiasis infection and Chagas disease. From 2011 to 2017, Sabin partnered with the Baylor College of Medicine and Texas Children’s Hospital in Houston, Texas, to carry out this work. Baylor College of Medicine continues this research as of May 2017 at the Texas Children’s Hospital’s Center for Vaccine Development.
Sabin is committed to supporting research to identify innovative solutions that will improve the lives of millions through immunization.